Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation

Kidney International

Volumn 70, Issue 10, 2006, Pages 1717-1724

  Kurata, A ^a   Nishizawa, H ^a   Kihara, S ^a   Maeda, N ^a   Sonoda, M ^a   Okada, T ^a   Ohashi, K ^a   Hibuse, T ^a   Fujita, K ^a   Yasui, A ^a   Hiuge, A ^a   Kumada, M ^a   Kuriyama, H ^a   Shimomura, I ^a   Funahashi, T ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adipocytokine; Adiponectin; Angiotensin II type1 receptor blocker; NADPH oxidase; Oxidative stress

Indexed keywords

ADIPOCYTOKINE; ANGIOTENSIN 2 RECEPTOR; OLMESARTAN;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; METABOLIC SYNDROME X; MOUSE; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

ADIPONECTIN; ADIPOSE TISSUE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ATHEROSCLEROSIS; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION; IMIDAZOLES; KIDNEY DISEASES; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; OBESITY; OXIDATIVE STRESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; SERUM AMYLOID A PROTEIN; SIGNAL TRANSDUCTION; TETRAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33750604403     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001810     Document Type: Article

References (61)

1. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
2. Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004; 140: 167-174.
3. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 2003; 16: 952-958.
4. Kambham N, Markowitz GS, Valeri AM et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-1509.
5. Wiecek A, Kokot F, Chudek J, Adamczak M. The adipose tissue - a novel endocrine organ of interest to the nephrologist. Nephrol Dial Transplant 2002; 17: 191-195.
6. Berl T, Hunsicker LG, Lewis JB et al. Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. J Am Soc Nephrol 2005; 16: 2170-2179.
7. Pontremoli R, Leoncini G, Ravera M et al. Microalbuminuria, cardiovascular, and renal risk in primary hypertension. J Am Soc Nephrol 2002; 13: S169-S172.
8. Anavekar NS, Gans DJ, Berl T et al. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl 2004; 92: S50-S55.
9. Hunsicker LG, Atkins RC, Lewis JB et al. Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the irbesartan diabetic nephropathy trial. Kidney Int Suppl 2004; 92: S99-S101.
10. Pontremoli R, Leoncini G, Viazzi F et al. Cardiovascular and renal risk assessment as a guide for treatment in primary hypertension. J Am Soc Nephrol 2004; 15: S34-S36.
11. Friedman AN, Hunsicker LG, Selhub J, Bostom AG. Collaborative Study Group Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy. J Am Soc Nephrol 2005; 16: 3397-3402.
12. Friedman AN, Hunsicker LG, Selhub J, Bostom AG, Collaborative Study Group. C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy. Kidney Int 2005; 68: 773-778.
13. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 1999; 18: 146-154.
14. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell 2001; 23: 531-543.
15. Shimomura I, Funahashi T, Takahashi M et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2: 800-803.
16. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
17. Matsuzawa Y, Funahashi T, Kihara S et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29-33.
18. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
19. Baud L, Fouqueray B, Philippe C et al. Tumor necrosis factor alpha and mesangial cells. Kidney Int 1992; 41: 600-603.
20. Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
21. Okamoto Y, Kihara S, Ouchi N et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106: 2767-2770.
22. Maeda N, Shimomura I, Kishida K, Nishizawa H et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8: 731-737.
23. Berg AH, Combs TP, Du X et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-953.
24. Pischon T, Girman CJ, Hotamisligil GS et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737.
25. Lindsay RS, Funahashi T, Hanson RL et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360: 57-58.
26. Mallamaci F, Zoccali C, Cuzzola F et al. Adiponectin in essential hypertension. J Nephrol 2002; 15: 507-511.
27. Adamczak M, Wiecek A, Funahashi T et al. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003; 16: 72-75.
28. Ryo M, Nakamura T, Kihara S et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68: 975-981.
29. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141.
30. Zoccali C, Mallamaci F, Tripepi G. Adipose tissue as a source of inflammatory cytokines in health and disease: focus on end-stage renal disease. Kidney Int Suppl 2003; 84: S65-S68.
31. Dzau VJ. Theodore Cooper lecture. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047-1052.
32. Wiecek A, Chudek J, Kokot F. Role of angiotensin II in the progression of diabetic nephropathy-therapeutic implications. Nephrol Dial Transplant 2003; 18(Suppl 5): v16-v20.
33. Dahlof B, Devereux RB, Kjeidsen SE et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
34. Parving HH, Lehnert H, Brochner-Mortensen J et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
35. Hunsicker LG. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control. J Manag Care Pharm 2004; 10: S12-S17.
36. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004; 30: 487-496.
37. Furuhashi M, Ura N, Higashiura K et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
38. Furukawa S, Fujita T, Shimabukuro M et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761.
39. Schmieder RE. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 2005; 18: 720-730.
40. Shiuchi T, Iwai M, Li HS et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004; 43: 1003-1010.
41. Fasshauer M, Klein J, Kralisch S et al. Serum amyloid A3 expression is stimulated by dexamethasone and interleukin-6 in 3T3-L1 adipocytes. J Endocrinol 2004; 183: 561-567.
42. Lin Y, Rajala MW, Berger JP et al. Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem 2001; 276: 42077-42083.
43. Tsuda M, Iwai M, Li JM et al. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension 2005; 45: 545-551.
44. Bendall JK, Cave AC, Heymes C et al. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 2002; 105: 293-296.
45. Li SL, Valente AJ, Zhao SJ, Clark RA. PU.1 is essential for p47(phox) promoter activity in myeloid cells. J Biol Chem 1997; 272: 17802-17809.
46. Akishita M, Nagai K, Xi H et al. Renin-angiotensin system modulates oxidative stress-induced endothelial cell apoptosis in rats. Hypertension 2005; 45: 1188-1193.
47. Hattori Y, Akimoto K, Gross SS et al. Angiotensin-II-induced oxidative stress elicits hypoadiponectinaemia in rats. Diabetologia 2005; 48: 1066-1074.
48. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
49. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
50. Onozato ML, Tojo A, Goto A et al. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002; 61: 186-194.
51. Usui M, Egashira K, Kitamoto S et al. Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats. Hypertension 1991; 34: 546-551.
52. Miyazaki Y, Mahankali A, Wajcberg E et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89: 4312-4319.
53. Maeda N, Takahashi M, Funahashi T et al. PPAR-gamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-2099.
54. Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gammamodulating activity. Hypertension 2004; 43: 993-1002.
55. Fujimoto M, Masuzaki H, Tanaka T et al. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett 2004; 576: 492-497.
56. Classen R, Schupp M, Foryst-Ludwig A et al. PPAR-gamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46: 137-143.
57. Griendling KK, Ushio-Fukai M. Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept 2000; 91: 21-27.
58. Ohtsu H, Frank GD, Utsunomiya H, Eguchi S. Redox-dependent protein kinase regulation by angiotensin II: mechanistic insights and its pathophysiology. Antioxid Redox Signal 2005; 7: 1315-1326.
59. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997; 100: 264-269.
60. McIntosh M, Hausman D, Martin R, Hausman G. Dehydroepiandrosterone attenuates preadipocyte growth in primary cultures of stromal-vascular cells. Am J Physiol 1998; 275: E285-293.
61. Wassmann S, Stumpf M, Strehlow K et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 2004; 94: 534-541.